Although HSC-1 cells expressed CCKBR, the CCKBR antagonist, YM022, did not affect the viability of either melanoma or SCC cells even at a dose 100 times that of the half-maximal inhibitory concentration (Figure 5c), suggesting that the CCK receptor antagonist decreases the viability of melanoma and SCC cells through CCKAR rather than through CCKBR. Here, CCKBR is linked to melanoma.